---
schema_version: "secwatch.filing_event.v1"
accession: "0001093557-23-000117"
form_type: "8-K"
ticker: "DXCM"
cik: "0001093557"
company_name: "DEXCOM INC"
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T08:04:25.373575+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Dexcom Q1 revenue $741.5M (+18% YoY); raises FY 2023 guidance to $3.4-3.515B

## Summary
- Revenue $741.5M (+18% YoY, +19% organic); US +17%, Intl +21% reported (+27% organic).
- GAAP net income $48.6M ($0.12 diluted EPS); Non-GAAP net income $68.5M ($0.17 diluted EPS).
- GAAP operating income $47.2M (6.4% revenue); Non-GAAP operating income $78.6M (10.6% revenue).
- Initiated Dexcom G7 launch in US; CMS finalized coverage for G7 for Medicare beneficiaries.
- FY 2023 revenue guidance raised to $3.4-3.515B (17-21% growth); margin guidance reiterated.

## SEC filing metadata
- accession: 0001093557-23-000117
- form_type: 8-K
- ticker: DXCM
- cik: 0001093557
- company_name: DEXCOM INC
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1093557/000109355723000117/0001093557-23-000117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1093557/000109355723000117/dxcm-20230427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001093557-23-000117
- JSON: https://secwatch.observer/filing/0001093557-23-000117.json
- Plain text: https://secwatch.observer/filing/0001093557-23-000117.txt

## Key facts
- Earnings Releases
  DEXCOM INC reported quarter ended March 31, 2023 results: revenue $741.5 million, net income $48.6 million, EPS $0.12 per diluted share. Guidance raised.
  - Period: quarter ended March 31, 2023
  - Revenue: $741.5 million
  - Net income: $48.6 million
  - EPS: $0.12 per diluted share
  - Guidance: raised
  - Result: reported results
  source text: its financial results as of and for the quarter ended March 31, 2023. First Quarter 2023 Financial Highlights: • Revenue grew 18% versus the same quarter of the prior year to $741.5 million on a reported basis and 19% on an organic 1 basis. • U.S. revenue growth of 17% and international revenue growth of 21% on a reported basis. International revenue growth was 27%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1093557/000109355723000117/0001093557-23-000117-index.htm
- Earnings Releases
  DEXCOM INC reported fiscal year 2023 results: revenue approximately $3.400 - 3.515 billion. Guidance raised.
  - Period: fiscal year 2023
  - Revenue: approximately $3.400 - 3.515 billion
  - Guidance: raised
  - Result: guidance update
  source text: The company is updating fiscal year 2023 revenue guidance, and reiterating guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin and Adjusted EBITDA Margin at the following levels: • Revenue of approximately $3.400 - 3.515 billion (17-21% growth)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1093557/000109355723000117/0001093557-23-000117-index.htm
- Earnings Releases
  DEXCOM INC reported first quarter of 2023 results: net income $48.6 million, EPS $0.12 per diluted share. Guidance raised.
  - Period: first quarter of 2023
  - Net income: $48.6 million
  - EPS: $0.12 per diluted share
  - Guidance: raised
  - Result: reported results
  source text: First Quarter 2023 Financial Results Revenue: In the first quarter of 2023, worldwide revenue grew 18% to $741.5 million on a reported basis, up from $628.8 million in the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1093557/000109355723000117/0001093557-23-000117-index.htm
- Earnings Releases
  DEXCOM INC reported first quarter of 2023 results: net income $48.6 million, EPS $0.12 per diluted share. Guidance raised.
  - Period: first quarter of 2023
  - Net income: $48.6 million
  - EPS: $0.12 per diluted share
  - Guidance: raised
  - Result: reported results
  source text: Given the strength of our first quarter results and an expanding market opportunity with new CGM coverage now available, we are pleased to raise our 2023 revenue guidance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1093557/000109355723000117/0001093557-23-000117-index.htm
- Earnings Releases
  DEXCOM INC reported first quarter of 2023 results: net income $48.6 million, EPS $0.12 per diluted share. Guidance raised.
  - Period: first quarter of 2023
  - Net income: $48.6 million
  - EPS: $0.12 per diluted share
  - Guidance: raised
  - Result: reported results
  source text: GAAP net income was $48.6 million, or $0.12 per diluted share, for the first quarter of 2023, compared to GAAP net income of $97.3 million, or $0.23 per diluted share, for the same quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1093557/000109355723000117/0001093557-23-000117-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.